文献速递湿疹皮炎与荨麻疹

阿利维A酸治疗儿童难治性手部湿疹及其他皮肤病的回顾性分析

Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-12-23

9例慢性手部湿疹中7例(78%)达中度至显著疗效,2例严重特应性皮炎中1例有效,1例常染色体隐性遗传性鱼鳞病有效。耐受性总体良好,头痛最常见(10例,77%),仅1例因此中断治疗。

要点

  • 阿利维A酸对儿童难治性慢性手部湿疹可能高度有效且安全。
  • 局部治疗无效的患儿可考虑使用,但需更大样本验证。

核心结论

  • 阿利维A酸对儿童慢性手部湿疹似乎高度有效且安全,可考虑用于局部治疗难治的患儿。

研究设计与样本

  • 主要结局指标为医生整体评估(PGA)。

主要发现

  • 9例慢性手部湿疹中7例(78%)PGA下降≥1分(中度至显著疗效)。
  • 2例严重特应性皮炎中1例有效,1例常染色体隐性遗传性鱼鳞病有效。
  • 其余4例未见确切疗效。
  • 头痛为最常见不良事件,见于10例(77%)治疗初期,仅1例因此中断治疗。

关键数值与推荐

  • PGA下降≥1分定义为中度至显著疗效。
  • 中位起始治疗年龄11.5岁(范围5.8–15.8岁)。

临床怎么用

  • 对局部治疗难治的儿童慢性手部湿疹可考虑阿利维A酸系统治疗。
  • 治疗初期需关注头痛,多数可耐受,少数需中断治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alitretinoin is a systemic retinoid licensed for use in adult patients suffering from chronic hand eczema recalcitrant to potent topical steroids. Experience with its use in childhood is lacking. OBJECTIVES: To report on the efficacy and safety of alitretinoin treatment in a cohort of children and adolescents with chronic hand eczema (CHE) and other inflammatory skin diseases. METHODS: We performed a retrospective chart review of all consecutive patients under the age of 18 years treated with alitretinoin at our paediatric skin centre. Physician's Global Assessment (PGA) was used as the primary outcome measure. RESULTS: Thirteen children (9 girls and 4 boys) were enrolled in this study. The median age at start of treatment with alitretinoin was 11.5 years (range 5.8-15.8 years). Nine children were diagnosed with CHE, two with severe atopic dermatitis (AD), and two with inherited ichthyosis [netherton syndrome (NS), autosomal recessive congenital ichthyosis (ARCI)]. Moderate to excellent response (PGA decrease of ≥1 point) was observed in 7 (78%) of the nine patients with CHE, one of the two patients with extensive AD and in the one patient with ARCI. In the remaining four subjects, no convincing effect was documented. Tolerability was overall very good. The most common adverse event was headache in 10 patients (77%) during the initiation of treatment, leading to interruption of therapy in one subject. CONCLUSIONS: Alitretinoin seems to be highly effective and safe for the treatment of paediatric CHE and should thus be considered in children with refractory disease under topical therapy. Larger studies are required to corroborate these findings.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Luchsinger I, Vogler T, Schwieger-Briel A, et al. Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis. J Eur Acad Dermatol Venereol. 2019. PMID: 31742759. doi:10.1111/jdv.16088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。